171 related articles for article (PubMed ID: 27780805)
1. Ceritinib Outperforms Chemo as Second-Line Treatment.
Cancer Discov; 2016 Dec; 6(12):OF5. PubMed ID: 27780805
[TBL] [Abstract][Full Text] [Related]
2. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
Kiura K; Imamura F; Kagamu H; Matsumoto S; Hida T; Nakagawa K; Satouchi M; Okamoto I; Takenoyama M; Fujisaka Y; Kurata T; Ito M; Tokushige K; Hatano B; Nishio M
Jpn J Clin Oncol; 2018 Apr; 48(4):367-375. PubMed ID: 29474558
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
Adv Ther; 2017 May; 34(5):1145-1156. PubMed ID: 28405961
[TBL] [Abstract][Full Text] [Related]
5. Ceritinib versus chemotherapy in ALK-positive lung cancer.
Marshall H
Lancet Respir Med; 2016 Dec; 4(12):952-953. PubMed ID: 27838332
[No Abstract] [Full Text] [Related]
6. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
Hida T; Satouchi M; Nakagawa K; Seto T; Matsumoto S; Kiura K; Nokihara H; Murakami H; Tokushige K; Hatano B; Nishio M
Jpn J Clin Oncol; 2017 Jul; 47(7):618-624. PubMed ID: 28369553
[TBL] [Abstract][Full Text] [Related]
7. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
8. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
9. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
[TBL] [Abstract][Full Text] [Related]
11. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].
Giroux Leprieur E; Fallet V; Wislez M
Bull Cancer; 2015 Dec; 102(12):1053-7. PubMed ID: 26597476
[TBL] [Abstract][Full Text] [Related]
12. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.
Bendaly E; Dalal AA; Culver K; Galebach P; Bocharova I; Foster R; Sasane M; Macalalad AR; Guérin A
Adv Ther; 2017 Jul; 34(7):1673-1685. PubMed ID: 28578501
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
14. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
15. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
16. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
[TBL] [Abstract][Full Text] [Related]
17. A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer.
Biya J; Caramella C; Lindsay CR; Planchard D; Besse B
J Thorac Oncol; 2015 Jun; 10(6):e44-5. PubMed ID: 26001149
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
[TBL] [Abstract][Full Text] [Related]
19. Second-generation ALK inhibitors: filling the non "MET" gap.
Ramalingam SS; Khuri FR
Cancer Discov; 2014 Jun; 4(6):634-6. PubMed ID: 24891360
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]